Search

Your search keyword '"Rerks-Ngarm, Supachai"' showing total 328 results
Start Over Author "Rerks-Ngarm, Supachai"
328 results on '"Rerks-Ngarm, Supachai"'

1. Prevalence of HPV infection among Thai schoolgirls in the north-eastern provinces in 2018: implications for HPV immunization policy

Author

Vongpunsawad, Sompong, Rhee, Chulwoo, Nilyanimit, Pornjarim, Poudyal, Nimesh, Jiamsiri, Suchada, Ahn, Hyeon Seon, Lee, Jinae, Seo, Hyeong-Won, Klinsupa, Worrawan, Park, Sunju, Premsri, Nakorn, Namwat, Chawetsan, Silaporn, Patummal, Excler, Jean-Louis, Kim, Deok-Ryun, Markowitz, Lauri E., Unger, Elizabeth R., Rerks-Ngarm, Supachai, Lynch, Julia, and Poovorawan, Yong

Published
2023
Full Text
View/download PDF

3. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques

Author

Santra, Sampa, Tomaras, Georgia D, Warrier, Ranjit, Nicely, Nathan I, Liao, Hua-Xin, Pollara, Justin, Liu, Pinghuang, Alam, S. Munir, Zhang, Ruijun, Cocklin, Sarah L, Shen, Xiaoying, Duffy, Ryan, Xia, Shi-Mao, Schutte, Robert J, Pemble IV, Charles W, Dennison, S. Moses, Li, Hui, Chao, Andrew, Vidnovic, Kora, Evans, Abbey, Klein, Katja, Kumar, Amit, Robinson, James, Landucci, Gary, Forthal, Donald N, Montefiori, David C, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Robb, Merlin L, Michael, Nelson L, Kim, Jerome H, Soderberg, Kelly A, Giorgi, Elena E, Blair, Lily, Korber, Bette T, Moog, Christiane, Shattock, Robin J, Letvin, Norman L, Schmitz, Joern E, Moody, M. A, Gao, Feng, Ferrari, Guido, Shaw, George M, Haynes, Barton F, and Douek, Daniel C

Published
2015

4. Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

Author

Edlefsen, Paul T, Rolland, Morgane, Hertz, Tomer, Tovanabutra, Sodsai, Gartland, Andrew J, deCamp, Allan C, Magaret, Craig A, Ahmed, Hasan, Gottardo, Raphael, Juraska, Michal, McCoy, Connor, Larsen, Brendan B, Sanders-Buell, Eric, Carrico, Chris, Menis, Sergey, Kijak, Gustavo H, Bose, Meera, RV144 Sequencing Team, Arroyo, Miguel A, O'Connell, Robert J, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Rerks-Ngarm, Supachai, Robb, Merlin L, Kirys, Tatsiana, Georgiev, Ivelin S, Kwong, Peter D, Scheffler, Konrad, Pond, Sergei L Kosakovsky, Carlson, Jonathan M, Michael, Nelson L, Schief, William R, Mullins, James I, Kim, Jerome H, and Gilbert, Peter B

Subjects
RV144 Sequencing Team, Humans, HIV-1, HIV Infections, AIDS Vaccines, Sequence Alignment, Sequence Analysis, Protein, Binding Sites, Genome, Viral, Models, Molecular, Molecular Sequence Data, Human Immunodeficiency Virus Proteins, Sequence Analysis, Protein, Genome, Viral, Models, Molecular, Mathematical Sciences, Biological Sciences, Information and Computing Sciences, Bioinformatics
Abstract

The RV144 clinical trial showed the partial efficacy of a vaccine regimen with an estimated vaccine efficacy (VE) of 31% for protecting low-risk Thai volunteers against acquisition of HIV-1. The impact of vaccine-induced immune responses can be investigated through sieve analysis of HIV-1 breakthrough infections (infected vaccine and placebo recipients). A V1/V2-targeted comparison of the genomes of HIV-1 breakthrough viruses identified two V2 amino acid sites that differed between the vaccine and placebo groups. Here we extended the V1/V2 analysis to the entire HIV-1 genome using an array of methods based on individual sites, k-mers and genes/proteins. We identified 56 amino acid sites or "signatures" and 119 k-mers that differed between the vaccine and placebo groups. Of those, 19 sites and 38 k-mers were located in the regions comprising the RV144 vaccine (Env-gp120, Gag, and Pro). The nine signature sites in Env-gp120 were significantly enriched for known antibody-associated sites (p = 0.0021). In particular, site 317 in the third variable loop (V3) overlapped with a hotspot of antibody recognition, and sites 369 and 424 were linked to CD4 binding site neutralization. The identified signature sites significantly covaried with other sites across the genome (mean = 32.1) more than did non-signature sites (mean = 0.9) (p < 0.0001), suggesting functional and/or structural relevance of the signature sites. Since signature sites were not preferentially restricted to the vaccine immunogens and because most of the associations were insignificant following correction for multiple testing, we predict that few of the genetic differences are strongly linked to the RV144 vaccine-induced immune pressure. In addition to presenting results of the first complete-genome analysis of the breakthrough infections in the RV144 trial, this work describes a set of statistical methods and tools applicable to analysis of breakthrough infection genomes in general vaccine efficacy trials for diverse pathogens.

Published
2015

6. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV 144 HIV Vaccine Efficacy Trial

Author

RV305 Study Team, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Excler, Jean-Louis, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Premsri, Nakorn, Kunasol, Prayura, Karasavvas, Nicos, Schuetz, Alexandra, Ngauy, Viseth, Sinangil, Faruk, Dawson, Peter, deCamp, Allan C., Phogat, Sanjay, Garunathan, Sanjay, Tartaglia, James, DiazGranados, Carlos, Ratto-Kim, Silvia, Pegu, Poonam, Eller, Michael, Karnasuta, Chitraporn, Montefiori, David C., Sawant, Sheetal, Vandergrift, Nathan, Wills, Saintedym, Tomaras, Georgia D., Robb, Merlin L., Michael, Nelson L., Kim, Jerome H., Vasan, Sandhya, and O'Connell, Robert J.

Published
2017

7. Editorial: AIDS 40th Year

Author

Zhou, Jiasheng, primary, Jiang, Shibo, additional, Zhou, Tongqing, additional, Chen, Zhiwei, additional, Jin, Xia, additional, Zhang, Wenyan, additional, Rerks-ngarm, Supachai, additional, Kramvis, Anna, additional, Deng, Kai, additional, and Zhang, Linqi, additional

Published
2023
Full Text
View/download PDF

8. Prevalence of HPV infection among Thai Schoolgirls in North-Eastern Provinces in 2018; Implication for HPV Immunization Policy

Author

Vongpunsawad, Sompong, primary, Rhee, Chulwoo, additional, Nilyanimit, Pornjarim, additional, Poudyal, Nimesh, additional, Jiamsiri, Suchada, additional, Ahn, Hyeon Seon, additional, Lee, Jinae, additional, Seo, Hyeong-Won, additional, Klinsupa, Worrawan, additional, Park, Sunju, additional, Premsri, Nakorn, additional, Namwat, Chawetsan, additional, Silaporn, Patummal, additional, Excler, Jean-Louis, additional, Kim, Deok-Ryun, additional, Markowitz, Lauri E., additional, Unger, Elizabeth R., additional, Rerks-Ngarm, Supachai, additional, Lynch, Julia, additional, and Poovorawan, Yong, additional

Published
2023
Full Text
View/download PDF

9. Systematic comparison of HIV-1 Envelope-specific IgG responses induced by different vaccination regimens: Can we steer IgG recognition towards regions of viral vulnerability?

Author

Horvath, Augusta, primary, Rogers, Lisa, additional, Pollakis, Georgios, additional, Baranov, Olga, additional, Pieroth, Nora, additional, Joseph, Sarah, additional, Chachage, Mkunde, additional, Heitzer, Asli, additional, Maganga, Lucas, additional, Msafiri, Frank, additional, Joachim, Agricola, additional, Viegas, Edna, additional, Eller, Leigh-Anne, additional, Kibuuka, Hannah, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayapan, Sorachai, additional, Dhitavat, Jittima, additional, Premsri, Nakorn, additional, Fidler, Sarah, additional, Shattock, Robin J., additional, Robb, Merlin Lee, additional, Weber, Jonathan, additional, McCormack, Sheena, additional, Munseri, Patricia Jane, additional, Lyamuya, Eligius, additional, Nilsson, Charlotta, additional, Kroidl, Arne, additional, Hoelscher, Michael, additional, Wagner, Ralf, additional, Geldmacher, Christof, additional, and Held, Kathrin, additional

Published
2023
Full Text
View/download PDF

10. Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses

Author

Fouda, Genevieve G., Cunningham, Coleen K., McFarland, Elizabeth J., Borkowsky, William, Muresan, Petronella, Pollara, Justin, Song, Lin Ye, Liebl, Brooke E., Whitaker, Kaylan, Shen, Xiaoying, Vandergrift, Nathan A., Overman, R. Glenn, Yates, Nicole L., Moody, M. Anthony, Fry, Carrie, Kim, Jerome H., Michael, Nelson L., Robb, Merlin, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Liao, Hua-Xin, Haynes, Barton F., Montefiori, David C., Ferrari, Guido, Tomaras, Georgia D., and Permar, Sallie R.

Published
2015

11. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.

Author

Williams, LaTonya D., Shen, Xiaoying, Sawant, Sheetal S., Akapirat, Siriwat, Dahora, Lindsay C., Tay, Matthew Zirui, Stanfield-Oakley, Sherry, Wills, Saintedym, Goodman, Derrick, Tenney, DeAnna, Spreng, Rachel L., Zhang, Lu, Yates, Nicole L., Montefiori, David C., Eller, Michael A., Easterhoff, David, Hope, Thomas J., Rerks-Ngarm, Supachai, Pittisuttithum, Punnee, and Nitayaphan, Sorachai

Subjects
GENETIC vectors, HIV, ANTIBODY formation, ANTIBODY specificity, IMMUNOGLOBULINS, ANTIBODY-dependent cell cytotoxicity, IMMUNE response
Abstract

The modestly efficacious HIV-1 vaccine regimen (RV144) conferred 31% vaccine efficacy at 3 years following the four-shot immunization series, coupled with rapid waning of putative immune correlates of decreased infection risk. New strategies to increase magnitude and durability of protective immunity are critically needed. The RV305 HIV-1 clinical trial evaluated the immunological impact of a follow-up boost of HIV-1-uninfected RV144 recipients after 6–8 years with RV144 immunogens (ALVAC-HIV alone, AIDSVAX B/E gp120 alone, or ALVAC-HIV + AIDSVAX B/E gp120). Previous reports demonstrated that this regimen elicited higher binding, antibody Fc function, and cellular responses than the primary RV144 regimen. However, the impact of the canarypox viral vector in driving antibody specificity, breadth, durability and function is unknown. We performed a follow-up analysis of humoral responses elicited in RV305 to determine the impact of the different booster immunogens on HIV-1 epitope specificity, antibody subclass, isotype, and Fc effector functions. Importantly, we observed that the ALVAC vaccine component directly contributed to improved breadth, function, and durability of vaccine-elicited antibody responses. Extended boosts in RV305 increased circulating antibody concentration and coverage of heterologous HIV-1 strains by V1V2-specific antibodies above estimated protective levels observed in RV144. Antibody Fc effector functions, specifically antibody-dependent cellular cytotoxicity and phagocytosis, were boosted to higher levels than was achieved in RV144. V1V2 Env IgG3, a correlate of lower HIV-1 risk, was not increased; plasma Env IgA (specifically IgA1), a correlate of increased HIV-1 risk, was elevated. The quality of the circulating polyclonal antibody response changed with each booster immunization. Remarkably, the ALVAC-HIV booster immunogen induced antibody responses post-second boost, indicating that the viral vector immunogen can be utilized to selectively enhance immune correlates of decreased HIV-1 risk. These results reveal a complex dynamic of HIV-1 immunity post-vaccination that may require careful balancing to achieve protective immunity in the vaccinated population. Trial registration: RV305 clinical trial (ClinicalTrials.gov number, NCT01435135). ClinicalTrials.gov Identifier: NCT00223080, ClinicalTrials.gov Identifier: NCT01931358, ClinicalTrials.gov Identifier: NCT01923610, ClinicalTrials.gov Identifier: NCT01461447. Author summary: One strategy for improving vaccine-elicited antibody durability is booster immunization. However, the impact of boosting on the quality of the polyclonal antibody response is not fully understood and may alter vaccine efficacy. We discovered that canarypox vector boost (ALVAC-HIV vectored vaccine component only) drove the recall of HIV-1-specific inverse correlate of risk (V2 IgG) and promoted more durable immunity. We found that delayed boosting increased the concentration of putative protective V1V2-specific IgG circulating in blood, enabling 80% of vaccinees to achieve this level in RV305 compared to 63% in RV144. In contrast to Env IgG1 and IgA1, Env IgG3 was not boosted. However, Env IgG1 correlated with the magnitude of the ADCP response, demonstrating that antibody function can be elevated independent of IgG3 and IgA1. By including a delayed boost as part of a HIV-1 prime-boost vaccine strategy, vaccine-elicited antibodies can reach the putative protective threshold in a larger proportion of the population. However, a second immunogen boost within a 6-month interval shifts the antibody isotype/subclass profile, resulting in decreased antibody functions. A canarypox prime regimen can drive antibody specificity and function. Our study informs selection of immunogen types and immunization intervals for HIV-1 vaccine developers to elicit protective immunity. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG

Author

Tomaras, Georgia D., Ferrari, Guido, Shen, Xiaoying, Alam, S. Munir, Liao, Hua-Xin, Pollara, Justin, Bonsignori, Mattia, Moody, M. Anthony, Fong, Youyi, Chen, Xi, Poling, Brigid, Nicholson, Cindo O., Zhang, Ruijun, Lu, Xiaozhi, Parks, Robert, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Gilbert, Peter B., Kim, Jerome H., Michael, Nelson L., Montefiori, David C., and Haynes, Barton F.

Published
2013

13. Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E

Author

Rerks-Ngarm, Supachai, Paris, Robert M., Chunsutthiwat, Supamit, Premsri, Nakorn, Namwat, Chawetsan, Bowonwatanuwong, Chureeratana, Li, Shuying S., Kaewkungkal, Jaranit, Trichavaroj, Rapee, Churikanont, Nampueng, de Souza, Mark S., Andrews, Charla, Francis, Donald, Adams, Elizabeth, Flores, Jorge, Gurunathan, Sanjay, Tartaglia, Jim, O'Connell, Robert J., Eamsila, Chirapa, Nitayaphan, Sorachai, Ngauy, Viseth, Thongcharoen, Prasert, Kunasol, Prayura, Michael, Nelson L., Robb, Merlin L., Gilbert, Peter B., and Kim, Jerome H.

Published
2013
Full Text
View/download PDF

14. HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders

Author

Janes, Holly, Herbeck, Joshua T., Tovanabutra, Sodsai, Thomas, Rasmi, Frahm, Nicole, Duerr, Ann, Hural, John, Corey, Lawrence, Self, Steve G., Buchbinder, Susan P., McElrath, M. Juliana, O'Connell, Robert J., Paris, Robert M., Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttihum, Punnee, Kaewkungwal, Jaranit, Robb, Merlin L., Michael, Nelson L., Mullins, James I., Kim, Jerome H., Gilbert, Peter B., and Rolland, Morgane

Subjects
Genetic variation -- Research, HIV infection -- Development and progression -- Diagnosis -- Research, Biological sciences, Health
Abstract

Given the variation in the HIV-1 viral load (VL) set point across subjects, as opposed to a fairly stable VL over time within an infected individual, it is important to identify the characteristics of the host and virus that affect VL set point. Although recently infected individuals with multiple phylogenetically linked HIV-1 founder variants represent a minority of HIV-1 infections, we found--in two different cohorts--that more diverse HIV-1 populations in early infection were associated with significantly higher VL 1 year after HIV-1 diagnosis., Approximately 20-35% of individuals become infected with multiple founder HIV-1 variants (1-3). We therefore sought to evaluate whether genetic characteristics of the founder viral populations could influence markers of clinical [...]

Published
2015
Full Text
View/download PDF

15. Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

Author

Montefiori, David C., Karnasuta, Chitraporn, Huang, Ying, Ahmed, Hasan, Gilbert, Peter, de Souza, Mark S., McLinden, Robert, Tovanabutra, Sodsai, Laurence-Chenine, Agnes, Sanders-Buell, Eric, Moody, M. Anthony, Bonsignori, Mattia, Ochsenbauer, Christina, Kappes, John, Tang, Haili, Greene, Kelli, Gao, Hongmei, LaBranche, Celia C., Andrews, Charla, Polonis, Victoria R., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Self, Steve G., Berman, Phillip W., Francis, Donald, Sinangil, Faruk, Lee, Carter, Tartaglia, Jim, Robb, Merlin L., Haynes, Barton F., Michael, Nelson L., and Kim, Jerome H.

Published
2012
Full Text
View/download PDF

16. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

Author

Robb, Merlin L, Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Kunasol, Prayura, Khamboonruang, Chirasak, Thongcharoen, Prasert, Morgan, Patricia, Benenson, Michael, Paris, Robert M, Chiu, Joseph, Adams, Elizabeth, Francis, Donald, Gurunathan, Sanjay, Tartaglia, Jim, Gilbert, Peter, Stablein, Don, Michael, Nelson L, and Kim, Jerome H

Published
2012
Full Text
View/download PDF

17. A community intervention effectiveness study of single dose or two doses of bivalent HPV vaccine (CERVARIX®) in female school students in Thailand

Author

Jiamsiri, Suchada, primary, Rhee, Chulwoo, additional, Ahn, Hyeon Seon, additional, Poudyal, Nimesh, additional, Seo, Hyeong-Won, additional, Klinsupa, Worrawan, additional, Nilyanimit, Pornjarim, additional, Premsri, Nakorn, additional, Namwat, Chawetsan, additional, Vonpunsawad, Sompong, additional, Chon, Yun, additional, Park, Sunju, additional, Kim, Deok-Ryun, additional, Unger, Elizabeth R., additional, Markowitz, Lauri, additional, Poovorawan, Yong, additional, Rerks-Ngarm, Supachai, additional, Excler, Jean Louis, additional, and Lynch, Julia, additional

Published
2022
Full Text
View/download PDF

18. A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination

Author

Lemke, Melissa M., primary, Theisen, Robert M., additional, Bozich, Emily R., additional, McLean, Milla R., additional, Lee, Christina Y., additional, Lopez, Ester, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Kratochvil, Sven, additional, Wines, Bruce D., additional, Hogarth, P. Mark, additional, Kent, Stephen J., additional, Chung, Amy W., additional, and Arnold, Kelly B., additional

Published
2022
Full Text
View/download PDF

19. Community Intervention of Single Dose or 2-Dose Regimen of Bivalent HPV Vaccine in Schoolgirls in Thailand - Vaccine Effectiveness 2 Years after Vaccination

Author

Jiamsiri, Suchada, primary, Rhee, Chulwoo, additional, Ahn, Hyeon Seon, additional, Seo, Hyeong Won, additional, Klinsupa, Worrawan, additional, Park, Sunju, additional, Lee, Jinae, additional, Premsri, Nakorn, additional, Namwat, Chawetsan, additional, Silaporn, Patummal, additional, Excler, Jean-Louis, additional, Kim, Deok Ryun, additional, Sampson, Joshua N., additional, Nilyanimit, Pornjarim, additional, Vongpunsawad, Sompong, additional, Poudyal, Nimesh, additional, Markowitz, Lauri E., additional, Panicker, Gitika, additional, Unger, Elizabeth R., additional, Rerks-Ngarm, Supachai, additional, Poovorawan, Yong, additional, and Lynch, Julia, additional

Published
2022
Full Text
View/download PDF

20. FCGR2C polymorphisms associate with hiv-1 vaccine protection in rv144 trial

Author

Li, Shuying S., Gilbert, Peter B., Tomaras, Georgia D., Kijak, Gustavo, Ferrari, Guido, Thomas, Rasmi, Pyo, Chul-Woo, Zolla-Pazner, Susan, Montefiori, David, Liao, Hua-Xin, Nabel, Gary, Pinter, Abraham, Evans, David T., Gottardo, Raphael, Dai, James Y., Janes, Holly, Morris, Daryl, Fong, Youyi, Edlefsen, Paul T., Li, Fusheng, Frahm, Nicole, Alpert, Michael D., Prentice, Heather, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Robb, Merlin L., O'Connell, Robert J., Haynes, Barton F., Michael, Nelson L., Kim, Jerome H., McElrath, M. Juliana, and Geraghty, Daniel E.

Subjects
Immunoglobulins -- Research -- Health aspects, Genetic polymorphisms -- Research, Clinical trials -- Analysis, Fc receptors -- Research, HIV infection -- Genetic aspects -- Research -- Risk factors -- Patient outcomes -- Development and progression, Health care industry
Abstract

The phase III RV144 HIV-1 vaccine trial estimated vaccine efficacy (VE) to be 31.2%. This trial demonstrated that the presence of HIV-1-specific IgG-binding Abs to envelope (Env) V1V2 inversely correlated with infection risk, while the presence of Env-specific plasma IgA Abs directly correlated with risk of HIV-1 infection. Moreover, Ab-dependent cellular cytotoxicity responses inversely correlated with risk of infection in vaccine recipients with low IgA; therefore, we hypothesized that vaccine-induced Fc receptor-mediated (FcR-mediated) Ab function is indicative of vaccine protection. We sequenced exons and surrounding areas of FcR-encoding genes and found one FCGR2C tag SNP (rs114945036) that associated with VE against HIV-1 subtype CRF01_AE, with lysine at position 169 (169K) in the V2 loop (CRF01_AE 169K). Individuals carrying CC in this SNP had an estimated VE of 15%, while individuals carrying CT or TT exhibited a VE of 91%. Furthermore, the rs114945036 SNP was highly associated with 3 other FCGR2CSNPs (rs138747765, rs78603008, and rs373013207). Env-specific IgG and IgG3 Abs, IgG avidity, and neutralizing Abs inversely correlated with CRF01_AE 169K HIV-1 infection risk in the CT- or TT carrying vaccine recipients only. These data suggest a potent role of Fc-γ receptors and Fc-mediated Ab function in conferring protection from transmission risk in the RV144 VE trial., Introduction The Thai phase III RV144 vaccine trial, which tested the ALVACHIV (vCP1521) prime and bivalent clade B/E recombinant gp120 boost vaccine regimen, showed an estimated vaccine efficacy (VE) of [...]

Published
2014
Full Text
View/download PDF

22. Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1

Author

Shangguan, Shida, primary, Ehrenberg, Philip K, additional, Geretz, Aviva, additional, Yum, Lauren, additional, Kundu, Gautam, additional, May, Kelly, additional, Fourati, Slim, additional, Nganou-Makamdop, Krystelle, additional, Williams, LaTonya D, additional, Sawant, Sheetal, additional, Lewitus, Eric, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Chariyalertsak, Suwat, additional, Rerks-Ngarm, Supachai, additional, Rolland, Morgane, additional, Douek, Daniel C, additional, Gilbert, Peter, additional, Tomaras, Georgia D, additional, Michael, Nelson L, additional, Vasan, Sandhya, additional, and Thomas, Rasmi, additional

Published
2021
Full Text
View/download PDF

23. Author response: Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1

Author

Shangguan, Shida, primary, Ehrenberg, Philip K, additional, Geretz, Aviva, additional, Yum, Lauren, additional, Kundu, Gautam, additional, May, Kelly, additional, Fourati, Slim, additional, Nganou-Makamdop, Krystelle, additional, Williams, LaTonya D, additional, Sawant, Sheetal, additional, Lewitus, Eric, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Chariyalertsak, Suwat, additional, Rerks-Ngarm, Supachai, additional, Rolland, Morgane, additional, Douek, Daniel C, additional, Gilbert, Peter, additional, Tomaras, Georgia D, additional, Michael, Nelson L, additional, Vasan, Sandhya, additional, and Thomas, Rasmi, additional

Published
2021
Full Text
View/download PDF

24. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth

Author

Li, Yifan, primary, Bai, Hongjun, additional, Sanders-Buell, Eric, additional, Dussupt, Vincent, additional, Townsley, Samantha, additional, Donofrio, Gina, additional, Bose, Meera, additional, O’Sullivan, Anne Marie, additional, Kibuuka, Hannah, additional, Maganga, Lucas, additional, Nitayaphan, Sorachai, additional, Kosgei, Josphat, additional, Pitisuttithum, Punnee, additional, Rerks-Ngarm, Supachai, additional, Eller, Leigh Anne, additional, Michael, Nelson L., additional, Robb, Merlin L., additional, Ake, Julie, additional, Vasan, Sandhya, additional, Tovanabutra, Sodsai, additional, Krebs, Shelly J., additional, and Rolland, Morgane, additional

Published
2021
Full Text
View/download PDF

25. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved

Author

Wiehe, Kevin, Easterhoff, David, Luo, Kan, Nicely, Nathan I., Bradley, Todd, Jaeger, Frederick H., Dennison, Moses S., Zhang, Ruijun, Lloyd, Krissey E., Stolarchuk, Christina, Parks, Robert, Sutherland, Laura L., Scearce, Richard M., Morris, Lynn, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Pitisuttithum, Punnee, Rerks-Ngarm, Supachai, Sinangil, Faruk, Phogat, Sanjay, Michael, Nelson L., Kim, Jerome H., Kelsoe, Garnett, Montefiori, David C., Tomaras, Georgia D., Bonsignori, Mattia, Santra, Sampa, Kepler, Thomas B., Alam, Munir S., Moody, Anthony M., Liao, Hua-Xin, and Haynes, Barton F.

Published
2014
Full Text
View/download PDF

26. RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection

Author

Lewitus, Eric, primary, Sanders-Buell, Eric, additional, Bose, Meera, additional, O’Sullivan, Anne Marie, additional, Poltavee, Kultida, additional, Li, Yifan, additional, Bai, Hongjun, additional, Mdluli, Thembi, additional, Donofrio, Gina, additional, Slike, Bonnie, additional, Zhao, Hong, additional, Wong, Kim, additional, Chen, Lennie, additional, Miller, Shana, additional, Lee, Jenica, additional, Ahani, Bahar, additional, Lepore, Steven, additional, Muhammad, Sevan, additional, Grande, Rebecca, additional, Tran, Ursula, additional, Dussupt, Vincent, additional, Mendez-Rivera, Letzibeth, additional, Nitayaphan, Sorachai, additional, Kaewkungwal, Jaranit, additional, Pitisuttithum, Punnee, additional, Rerks-Ngarm, Supachai, additional, O’Connell, Robert J, additional, Janes, Holly, additional, Gilbert, Peter B, additional, Gramzinski, Robert, additional, Vasan, Sandhya, additional, Robb, Merlin L, additional, Michael, Nelson L, additional, Krebs, Shelly J, additional, Herbeck, Joshua T, additional, Edlefsen, Paul T, additional, Mullins, James I, additional, Kim, Jerome H, additional, Tovanabutra, Sodsai, additional, and Rolland, Morgane, additional

Published
2021
Full Text
View/download PDF

27. Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as the primary mechanism of vaccine-induced protection against HIV-1

Author

Shangguan, Shida, primary, Ehrenberg, Philip K., additional, Geretz, Aviva, additional, Yum, Lauren, additional, Kundu, Gautam, additional, May, Kelly, additional, Fourati, Slim, additional, Nganou-Makamdop, Krystelle, additional, Williams, LaTonya D., additional, Sawant, Sheetal, additional, Lewitus, Eric, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Chariyalertsak, Suwat, additional, Rerks-Ngarm, Supachai, additional, Rolland, Morgane, additional, Douek, Daniel, additional, Gilbert, Peter, additional, Tomaras, Georgia D., additional, Michael, Nelson, additional, Vasan, Sandhya, additional, and Thomas, Rasmi, additional

Published
2021
Full Text
View/download PDF

28. Immune Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Author

Haynes, Barton F., Gilbert, Peter B., Juliana McElrath, M., Zolla-Pazner, Susan, Tomaras, Georgia D., Munir Alam, S., Evans, David, Montefiori, David, Karnasuta, Chitraporn, Sutthent, Ruengpueng, Liao, Hua-Xin, DeVico, Anthony, Lewis, George, Williams, Constance, Pinter, Abraham, Fong, Youyi, Janes, Holly, DeCamp, Allan, Huang, Yunda, Rao, Mangala, Billings, Erik, Karasavvas, Nicos, Robb, Merlin L., Ngauy, Viseth, de Souza, Mark S., Paris, Robert, Ferrari, Guido, Bailer, Robert T., Soderberg, Kelly A., Andrews, Charla, Berman, Phillip, Frahm, Nicole, De Rosa, Stephen C., Alpert, Michael D., Yates, Nicole L., Shen, Xiaoying, Koup, Richard A., Pitisuttithum, Punnee, Kaewkungwal, Jaranit, Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Michael, Nelson L., and Kim, Jerome H.

Published
2012

29. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Author

Rerks-Ngarm, Supachai, Pitisutthum, Punnee, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Chiu, Joseph, Paris, Robert, Premsri, Nakorn, Namwat, Chawetsan, de Souza, Mark, Adams, Elizabeth, Benenson, Michael, Gurunathan, Sanjay, Tartaglia, Jim, McNeil, John G., Francis, Donald P., Stablein, Donald, Birx, Deborah L., Chunsuttiwat, Supamit, Khamboonruang, Chirasak, Thongcharoen, Prasert, Robb, Merlin L., Michael, Nelson L., Kunasol, Prayura, and Kim, Jerome H.

Subjects
HIV infection -- Prevention, Heterosexuals -- Health aspects, AIDS vaccines -- Usage, AIDS vaccines -- Health aspects, Abacavir -- Usage, Abacavir -- Health aspects, Thailand -- Health aspects
Abstract

A study was conducted to evaluate the efficacy and safety of ALVAC-HIV and AIDSVAX B/E vaccination in order to prevent HIV-1 infection in Thailand. Results indicated that such vaccines were effective in reducing the risk of HIV infection in a largely heterosexual population; however, did not affect the CD4+ count in HIV patients.

Published
2009

30. Correction: RV144 HIV-1 vaccination impacts post-infection antibody responses

Author

Mdluli, Thembi, primary, Jian, Ningbo, additional, Slike, Bonnie, additional, Paquin-Proulx, Dominic, additional, Donofrio, Gina, additional, Alrubayyi, Aljawharah, additional, Gift, Syna, additional, Grande, Rebecca, additional, Bryson, Mary, additional, Lee, Anna, additional, Dussupt, Vincent, additional, Mendez-Rivera, Letzibeth, additional, Sanders-Buell, Eric, additional, Chenine, Agnès-Laurence, additional, Tran, Ursula, additional, Li, Yifan, additional, Brown, Eric, additional, Edlefsen, Paul T., additional, O’Connell, Robert, additional, Gilbert, Peter, additional, Nitayaphan, Sorachai, additional, Pitisuttihum, Punnee, additional, Rerks-Ngarm, Supachai, additional, Robb, Merlin L., additional, Gramzinski, Robert, additional, Alter, Galit, additional, Tovanabutra, Sodsai, additional, Georgiev, Ivelin S., additional, Ackerman, Margaret E., additional, Polonis, Victoria R., additional, Vasan, Sandhya, additional, Michael, Nelson L., additional, Kim, Jerome H., additional, Eller, Michael A., additional, Krebs, Shelly J., additional, and Rolland, Morgane, additional

Published
2021
Full Text
View/download PDF

31. Editorial: AIDS 40th Year.

Author

Jiasheng Zhou, Shibo Jiang, Tongqing Zhou, Zhiwei Chen, Xia Jin, Wenyan Zhang, Rerks-ngarm, Supachai, Kramvis, Anna, Kai Deng, and Linqi Zhang

Subjects
HIV, VIROLOGY
Published
2023
Full Text
View/download PDF

32. RV144 HIV-1 vaccination impacts post-infection antibody responses

Author

Mdluli, Thembi, primary, Jian, Ningbo, additional, Slike, Bonnie, additional, Paquin-Proulx, Dominic, additional, Donofrio, Gina, additional, Alrubayyi, Aljawharah, additional, Gift, Syna, additional, Grande, Rebecca, additional, Bryson, Mary, additional, Lee, Anna, additional, Dussupt, Vincent, additional, Mendez-Riveria, Letzibeth, additional, Sanders-Buell, Eric, additional, Chenine, Agnès-Laurence, additional, Tran, Ursula, additional, Li, Yifan, additional, Brown, Eric, additional, Edlefsen, Paul T., additional, O’Connell, Robert, additional, Gilbert, Peter, additional, Nitayaphan, Sorachai, additional, Pitisuttihum, Punnee, additional, Rerks-Ngarm, Supachai, additional, Robb, Merlin L., additional, Gramzinski, Robert, additional, Alter, Galit, additional, Tovanabutra, Sodsai, additional, Georgiev, Ivelin S., additional, Ackerman, Margaret E., additional, Polonis, Victoria R., additional, Vasan, Sandhya, additional, Michael, Nelson L., additional, Kim, Jerome H., additional, Eller, Michael A., additional, Krebs, Shelly J., additional, and Rolland, Morgane, additional

Published
2020
Full Text
View/download PDF

34. Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2

Author

Liao, Hua-Xin, Bonsignori, Mattia, Alam, Munir S., McLellan, Jason S., Tomaras, Georgia D., Moody, Anthony M., Kozink, Daniel M., Hwang, Kwan-Ki, Chen, Xi, Tsao, Chun-Yen, Liu, Pinghuang, Lu, Xiaozhi, Parks, Robert J., Montefiori, David C., Ferrari, Guido, Pollara, Justin, Rao, Mangala, Peachman, Kristina K., Santra, Sampa, Letvin, Norman L., Karasavvas, Nicos, Yang, Zhi-Yong, Dai, Kaifan, Pancera, Marie, Gorman, Jason, Wiehe, Kevin, Nicely, Nathan I., Rerks-Ngarm, Supachai, Nitayaphan, Sorachai, Kaewkungwal, Jaranit, Pitisuttithum, Punnee, Tartaglia, James, Sinangil, Faruk, Kim, Jerome H., Michael, Nelson L., Kepler, Thomas B., Kwong, Peter D., Mascola, John R., Nabel, Gary J., Pinter, Abraham, Zolla-Pazner, Susan, and Haynes, Barton F.

Published
2013
Full Text
View/download PDF

35. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

Author

Rolland, Morgane, Edlefsen, Paul T., Larsen, Brendan B., Tovanabutra, Sodsai, Sanders-Buell, Eric, Hertz, Tomer, deCamp, Allan C., Carrico, Chris, Menis, Sergey, Magaret, Craig A., Ahmed, Hasan, Juraska, Michal, Chen, Lennie, Konopa, Philip, Nariya, Snehal, Stoddard, Julia N., Wong, Kim, Zhao, Hong, Deng, Wenjie, Maust, Brandon S., Bose, Meera, Howell, Shana, Bates, Adam, Lazzaro, Michelle, O’Sullivan, Annemarie, Lei, Esther, Bradfield, Andrea, Ibitamuno, Grace, Assawadarachai, Vatcharain, O’Connell, Robert J., deSouza, Mark S., Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Robb, Merlin L., McLellan, Jason S., Georgiev, Ivelin, Kwong, Peter D., Carlson, Jonathan M., Michael, Nelson L., Schief, William R., Gilbert, Peter B., Mullins, James I., and Kim, Jerome H.

Published
2012
Full Text
View/download PDF

36. Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response

Author

Fischinger, Stephanie, primary, Shin, Sally, additional, Boudreau, Carolyn M., additional, Ackerman, Margaret, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Kim, Jerome H., additional, Robb, Merlin L., additional, Michael, Nelson L., additional, O’Connell, Robert J., additional, Vasan, Sandhya, additional, Streeck, Hendrik, additional, and Alter, Galit, additional

Published
2020
Full Text
View/download PDF

37. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

Author

Easterhoff, David, primary, Pollara, Justin, additional, Luo, Kan, additional, Tolbert, William D., additional, Young, Brianna, additional, Mielke, Dieter, additional, Jha, Shalini, additional, O’Connell, Robert J., additional, Vasan, Sandhya, additional, Kim, Jerome, additional, Michael, Nelson L., additional, Excler, Jean-Louis, additional, Robb, Merlin L., additional, Rerks-Ngarm, Supachai, additional, Kaewkungwal, Jaranit, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Sinangil, Faruk, additional, Tartaglia, James, additional, Phogat, Sanjay, additional, Kepler, Thomas B., additional, Alam, S. Munir, additional, Wiehe, Kevin, additional, Saunders, Kevin O., additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, Moody, M. Anthony, additional, Pazgier, Marzena, additional, Haynes, Barton F., additional, and Ferrari, Guido, additional

Published
2020
Full Text
View/download PDF

38. HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions

Author

Easterhoff, David, primary, Pollara, Justin, additional, Luo, Kan, additional, Janus, Benjamin, additional, Gohain, Neelakshi, additional, Williams, LaTonya D., additional, Tay, Matthew Zirui, additional, Monroe, Anthony, additional, Peachman, Kristina, additional, Choe, Misook, additional, Min, Susie, additional, Lusso, Paolo, additional, Zhang, Peng, additional, Go, Eden P., additional, Desaire, Heather, additional, Bonsignori, Mattia, additional, Hwang, Kwan-Ki, additional, Beck, Charles, additional, Kakalis, Matina, additional, O’Connell, Robert J., additional, Vasan, Sandhya, additional, Kim, Jerome H., additional, Michael, Nelson L., additional, Excler, Jean-Louis, additional, Robb, Merlin L., additional, Rerks-Ngarm, Supachai, additional, Kaewkungwal, Jaranit, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Sinangil, Faruk, additional, Tartaglia, James, additional, Phogat, Sanjay, additional, Wiehe, Kevin, additional, Saunders, Kevin O., additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, Moody, M. Anthony, additional, Arthos, James, additional, Rao, Mangala, additional, Joyce, M. Gordon, additional, Ofek, Gilad A., additional, Ferrari, Guido, additional, and Haynes, Barton F., additional

Published
2020
Full Text
View/download PDF

39. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans

Author

Zhao, Lue Ping, primary, Fiore-Gartland, Andrew, additional, Carpp, Lindsay N., additional, Cohen, Kristen W., additional, Rouphael, Nadine, additional, Fleurs, Llewellyn, additional, Dintwe, One, additional, Zhao, Michael, additional, Moodie, Zoe, additional, Fong, Youyi, additional, Garrett, Nigel, additional, Huang, Ying, additional, Innes, Craig, additional, Janes, Holly E., additional, Lazarus, Erica, additional, Michael, Nelson L., additional, Nitayaphan, Sorachai, additional, Pitisuttithum, Punnee, additional, Rerks-Ngarm, Supachai, additional, Robb, Merlin L., additional, De Rosa, Stephen C., additional, Corey, Lawrence, additional, Gray, Glenda E., additional, Seaton, Kelly E., additional, Yates, Nicole L., additional, McElrath, M. Juliana, additional, Frahm, Nicole, additional, Tomaras, Georgia D., additional, and Gilbert, Peter B., additional

Published
2020
Full Text
View/download PDF

42. HIV-1 subtypes and male-to-female transmission in Thailand

Author

Kunanusont, Chaiyos, Foy, Hjordis M., Kreiss, Joan K., Rerks-Ngarm, Supachai, Phanuphak, Praphan, Raktham, Suwanee, Pau, Chou-Pong, and Young, Nancy L.

Subjects
HIV (Viruses), Heterosexuals -- Health aspects, HIV infection -- Risk factors, Intravenous drug abuse -- Health aspects
Published
1995

43. Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity

Author

Easterhoff, David, primary, Pollara, Justin, additional, Luo, Kan, additional, Tolbert, William D., additional, Young, Brianna, additional, Mielke, Dieter, additional, Jha, Shalini, additional, O’Connell, Robert J., additional, Vasan, Sandhya, additional, Kim, Jerome, additional, Michael, Nelson L., additional, Excler, Jean-Louis, additional, Robb, Merlin L., additional, Rerks-Ngarm, Supachai, additional, Kaewkungwal, Jaranit, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, Sinangil, Faruk, additional, Tartaglia, James, additional, Phogat, Sanjay, additional, Kepler, Thomas B., additional, Alam, S. Munir, additional, Wiehe, Kevin, additional, Saunders, Kevin O., additional, Montefiori, David C., additional, Tomaras, Georgia D., additional, Moody, M. Anthony, additional, Pazgier, Marzena, additional, Haynes, Barton F., additional, and Ferrari, Guido, additional

Published
2019
Full Text
View/download PDF

44. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans

Author

Pissani, Franco, primary, Schulte, Bianca, additional, Eller, Michael A., additional, Schultz, Bruce T., additional, Ratto-Kim, Silvia, additional, Marovich, Mary, additional, Thongcharoen, Prasert, additional, Sriplienchan, Somchai, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Esser, Stefan, additional, Alter, Galit, additional, Robb, Merlin L., additional, Kim, Jerome H., additional, Michael, Nelson L., additional, and Streeck, Hendrik, additional

Published
2018
Full Text
View/download PDF

45. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying env from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism

Author

Scinto, Hanna B., primary, Gupta, Sandeep, additional, Thorat, Swati, additional, Mukhtar, Muhammad M., additional, Griffiths, Anthony, additional, Delgado, Jennifer, additional, Plake, Elizabeth, additional, Vyas, Hemant K., additional, Strickland, Amanda, additional, Byrareddy, Siddappa N., additional, Montefiori, David C., additional, LaBranche, Celia, additional, Pal, Ranajit, additional, Treece, Jim, additional, Orndorff, Sharon, additional, Ferrari, Maria Grazia, additional, Weiss, Deborah, additional, Chenine, Agnes-Laurence, additional, McLinden, Robert, additional, Michael, Nelson, additional, Kim, Jerome H., additional, Robb, Merlin L., additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayaphan, Sorachai, additional, and Ruprecht, Ruth M., additional

Published
2018
Full Text
View/download PDF

46. HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees

Author

Yates, Nicole L., primary, deCamp, Allan C., additional, Korber, Bette T., additional, Liao, Hua-Xin, additional, Irene, Carmela, additional, Pinter, Abraham, additional, Peacock, James, additional, Harris, Linda J., additional, Sawant, Sheetal, additional, Hraber, Peter, additional, Shen, Xiaoying, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayapan, Sorachai, additional, Berman, Phillip W., additional, Robb, Merlin L., additional, Pantaleo, Giuseppe, additional, Zolla-Pazner, Susan, additional, Haynes, Barton F., additional, Alam, S. Munir, additional, Montefiori, David C., additional, and Tomaras, Georgia D., additional

Published
2018
Full Text
View/download PDF

47. HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis

Author

Wills, Saintedym, primary, Hwang, Kwan-Ki, additional, Liu, Pinghuang, additional, Dennison, S. Moses, additional, Tay, Matthew Zirui, additional, Shen, Xiaoying, additional, Pollara, Justin, additional, Lucas, Judith T., additional, Parks, Robert, additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayapan, Sorachai, additional, Kaewkungwal, Jaranit, additional, Thomas, Rasmi, additional, Kim, Jerome H., additional, Michael, Nelson L., additional, Robb, Merlin L., additional, McRaven, Mike, additional, Montefiori, David C., additional, Hope, Thomas J., additional, Liao, Hua-Xin, additional, Moody, M. Anthony, additional, Ferrari, Guido, additional, Haynes, Barton F., additional, Alam, S. Munir, additional, Bonsignori, Mattia, additional, and Tomaras, Georgia D., additional

Published
2018
Full Text
View/download PDF

48. Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection

Author

Auclair, Sarah, primary, Liu, Fengliang, additional, Niu, Qingli, additional, Hou, Wei, additional, Churchyard, Gavin, additional, Morgan, Cecilia, additional, Frahm, Nicole, additional, Nitayaphan, Sorachai, additional, Pitisuthithum, Punnee, additional, Rerks-Ngarm, Supachai, additional, Kimata, Jason T., additional, Soong, Lynn, additional, Franchini, Genoveffa, additional, Robb, Merlin, additional, Kim, Jerome, additional, Michael, Nelson, additional, and Hu, Haitao, additional

Published
2018
Full Text
View/download PDF

49. AIDS Vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines

Author

Kent, Stephen J., Cooper, David A., Vun, Mean Chhi, Shao, Yiming, Zhang, Linqi, Ganguly, Nirmal, Bela, Budiman, Tamashiro, Hiko, Ditangco, Rossana, Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Van Kinh, Nguyen, Bernstein, Alan, and Osmanov, Saladin

Subjects
AIDS vaccines -- Product development -- Usage -- Health aspects, HIV infection -- Drug therapy -- Prevention -- Health aspects, Biological sciences
Abstract

The Challenge The HIV/AIDS pandemic continues to spread and an AIDS vaccine is urgently needed. While facing unprecedented challenges, AIDS vaccine development activities are continuing around the globe [1, 2]. [...]

Published
2010
Full Text
View/download PDF

50. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1

Author

Wang, Kening, primary, Tomaras, Georgia D., additional, Jegaskanda, Sinthujan, additional, Moody, M. Anthony, additional, Liao, Hua-Xin, additional, Goodman, Kyle N., additional, Berman, Phillip W., additional, Rerks-Ngarm, Supachai, additional, Pitisuttithum, Punnee, additional, Nitayapan, Sorachai, additional, Kaewkungwal, Jaranit, additional, Haynes, Barton F., additional, and Cohen, Jeffrey I., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results